Business Description
Senti Biosciences is a clinical-stage biotech company focused on developing advanced cell and gene therapies for patients with serious, hard-to-treat diseases. Its core technology uses specially engineered natural killer cells drawn from healthy donors, which are then equipped with gene circuit systems designed to more precisely target cancer cells while protecting healthy tissue. The company's lead programs, SENTI-202 and SENTI-301A, address blood cancers and liver tumors respectively, and it has partnered with Celest Therapeutics in Shanghai to advance its solid tumor treatment into clinical trials. Founded in 2016 and based in South San Francisco, Senti Biosciences also maintains a broader pipeline of early-stage programs spanning additional cancer treatments and regenerative medicine.
